Trials / Recruiting
RecruitingNCT06410976
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- QED Therapeutics, a BridgeBio company · Industry
- Sex
- All
- Age
- 30 Months – 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Detailed description
The objective is to evaluate growth, HCH-related medical complications, health-related quality of life, functional abilities and cognitive functions of study participants. Data collected will contribute to the characterization of the natural history of children with HCH. No study medication will be administered.
Conditions
Timeline
- Start date
- 2024-06-05
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-05-13
- Last updated
- 2025-10-10
Locations
25 sites across 10 countries: United States, Australia, Canada, France, Norway, Portugal, Singapore, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT06410976. Inclusion in this directory is not an endorsement.